Pituitary tumors: Pathophysiology, clinical manifestations and management

Endocrine-Related Cancer

Volumn 8, Issue 4, 2001, Pages 287-305

  Arafah, B M ^a   Nasrallah, M P ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYPROHEPTADINE; DESMOPRESSIN; DEXAMETHASONE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; FOLLITROPIN; GONADOTROPIN; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; KETOCONAZOLE; LANREOTIDE SR; LUTEINIZING HORMONE; METYRAPONE; OCTREOTIDE; PEGVISOMANT; PERGOLIDE; PROLACTIN; RECEPTOR BLOCKING AGENT; RECOMBINANT GROWTH HORMONE; SEROTONIN ANTAGONIST; SOMATOSTATIN DERIVATIVE; TESTOSTERONE ENANTATE; THYROTROPIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACROMEGALY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUSHING SYNDROME; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; GASTROINTESTINAL TOXICITY; GROWTH HORMONE DEFICIENCY; HUMAN; HYPERCORTISOLISM; HYPERPROLACTINEMIA; HYPOGONADISM; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; HYPOPITUITARISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NELSON SYNDROME; ORTHOSTATIC HYPOTENSION; PREGNANCY; PROLACTINOMA; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ACROMEGALY; ADENOMA; ADRENOCORTICOTROPIC HORMONE; ADULT; CASE MANAGEMENT; CHILD; CLONE CELLS; COMBINED MODALITY THERAPY; DIABETES INSIPIDUS, NEUROGENIC; DOPAMINE AGONISTS; FALSE NEGATIVE REACTIONS; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; HYPOPHYSECTOMY; HYPOPITUITARISM; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INCIDENCE; MALE; MIDDLE AGED; NELSON SYNDROME; OCTREOTIDE; PITUITARY FUNCTION TESTS; PITUITARY HORMONES; PITUITARY NEOPLASMS; PITUITARY-ADRENAL SYSTEM; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PREVALENCE; PROLACTIN; PROLACTINOMA; STAINING AND LABELING;

EID: 0035660835     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0080287     Document Type: Review

References (92)

1. Metastatic tumors to the pituitary
2. Cabergoline in the treatment of acromegaly: A study in 64 patients
3. A polymorphism in the growth hormone (GH)-releasing hormone (GHRH) receptor gene is associated with elevated response to GHRH by human pituitary somatotrophinomas in vitro
4. Clinically nonfunctioning pituitary tumors are monoclonal in origin
5. Cushing's syndrome
6. Gradual recovery of lactotroph responsiveness to dynamic stimulation following surgical removal of prolactinomas: Long term follow-up studies
7. Value of growth hormone dynamics and somatomedin-C (insulin-like growth factor-1) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly
8. Immediate recovery of pituitary function after transsphenoidal resection of pituitary macroadenomas
9. Clinical manifestations and management of hypopituitarism
10. Pituitary tumor apoplexy: Pathophysiology, clinical manifestations, and management
11. The dominant role of increased intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches in patients with pituitary adenomas
12. Preoperative treatment of acromegaly with long acting somatostatin analog SMS 201-995: Shrinkage of invasive pituitary macroadenomas and improved surgical remission rate
13. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years
14. Criteria for medical as opposed to surgical treatment of prolactinomas
15. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly
16. Microadenomas of the pituitary and abnormal sellar tomograms in unselected autopsy series
17. Efficacy of the long-acting octreotide formulation (octreotide-Lar) in patients with thyrotropin- secreting pituitary adenomas
18. Recent developments in gene therapy: Applications for the treatment of pituitary tumours
19. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients
20. Insulin-like growth factor binding protein-3 levels during early and late follow-up after surgery in acromegalic patients
21. Diagnosis and drug therapy of prolactinomas
22. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients
23. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut
24. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly
25. Recognition of gonadotroph adenomas in women
26. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly
27. Clinical aspects of growth hormone deficiency in adults
28. The expanding spectrum of G protein diseases
29. Methylation mechanisms in pituitary tumorigenesis
30. Extensive personal experience: Transsphenoidal pituitary resection for preoperative diagnosis of prolactin- secreting pituitary adenoma in women: Long term follow-up
31. Newer diagnostic techniques and problems in Cushing's disease
32. Differential diagnosis of sellar masses
33. Clinical review 110: Diagnosis and treatment of pituitary tumors
34. Psychological features of acromegaly
35. Gamma knife treatment of pituitary adenomas
36. Thyrotropin-secreting pituitary adenomas: Clinical and biochemical heterogeneity. Case reports and follow-up of nine patients
37. Criteria for cure of acromegaly: A consensus statement
38. Diagnosis, treatment and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients
39. Pituitary magnetic resonance imaging in normal human volunteers: Occult adenomas in the general population
40. Octapeptide somatostatin-analogue therapy of Cushing's syndrome
41. Evaluation of the hypothalamic pituitary adrenal axis immediately after pituitary adenomectomy: Is perioperative steroid therapy necessary?
42. Management of incidental pituitary microadenomas: A cost-effectiveness analysis
43. Diagnosis and management of hormone-secreting pituitary adenomas
44. Gastric inhibitory polypeptide-dependent cortisol hypersecretion. A new cause of Cushing's syndrome
45. Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas
46. The outcome of surgery for acromegaly: The need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma
47. Carcinomas of the pituitary: Definition and review of the literature
48. New technique for quantitation of pituitary adenoma size: Use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist
49. Acromegaly
50. Pathogenesis of pituitary tumors
51. Pituitary tumors secreting growth hormone and prolactin
52. Current treatment guidelines for acromegaly
53. Age-related and gender-related occurrence of pituitary tumors
54. Pregnancy and the hyperprolactinemic woman
55. The pituitary incidentaloma
56. Bromocriptine as primary treatment for prolactin-secreting macroadenomas: Results of a prospective multicenter study
57. Management of prolactinomas: Overview and introduction
58. Therapeutic strategy for incidentally found pituitary tumors
59. Prevalence of alpha subunit hypersecretion in patients with pituitary tumors: Clinically non-functioning and somatotroph adenomas
60. Cushing's syndrome
61. A single midnight serum cortisol measurement distinguishes Cushing's syndrome from pseudo-Cushing states
62. Growth hormone receptor antagonists therapy for acromegaly
63. Radiotherapy for pituitary tumors
64. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure
65. Testosterone-related exacerbation of a prolactin-producing macroadenoma: Possible role for estrogen
66. Late-night salivary cortisol as a screening test for Cushing's syndrome
67. Glycoprotein-secreting pituitary adenomas
68. Growth hormone-releasing hormone-producing tumors: Clinical, biochemical and morphological manifestations
69. Myocardial dysfunction in treated adult hypopituitarism: A possible mechanism for increased cardiovascular mortality
70. Management of pituitary tumors
71. Medical therapy for gonadotroph and thyrotroph tumors
72. The management of diabetes insipidus in adults
73. Extensive personal experience: Gonadotroph adenomas
74. Thyrotropin (TSH)-induced hyperthyroidism: Response of TSH to dopamine and its agonists
75. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas
76. The future of somatostatin analogue therapy
77. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
78. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men
79. Polycythemia vera in acromegaly
80. Treatment of acromegaly with the growth hormone receptor antagonist pegvisomant
81. Advances in the diagnosis and treatment of Cushing's syndrome
82. Transsphenoidal surgery for microprolactinoma: An acceptable alternative to dopamine agonists?
83. Cushing's disease
84. Transsphenoidal microsurgical therapy of prolactinomas: Initial outcomes and long-term results
85. Early postoperative growth hormone levels: High predictive value for long-term outcome after surgery for acromegaly
86. Hypopituitarism
87. Growth hormone therapy in adults and children
88. Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly
89. Clinical management of prolactinomas
90. Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses estrogen-induced pituitary prolactinomas
91. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration
92. Gonadotroph adenoma of the pituitary gland: A clinicopathologic analysis of 100 cases